TY  - JOUR
A1  - Lisowski, Dominik
A1  - Hartrampf, Philipp E.
A1  - Hasenauer, Natalie
A1  - Nickl, Vera
A1  - Monoranu, Camelia-Maria
A1  - Tamihardja, Jörg
T1  - Complete loss of E-cadherin expression in a rare case of metastatic malignant meningioma: a case report
JF  - BMC Neurology
N2  - Background
Hematogenous tumor spread of malignant meningiomas occurs very rarely but is associated with very poor prognosis.

Case presentation
We report an unusual case of a patient with a malignant meningioma who developed multiple metastases in bones, lungs and liver after initial complete resection of the primary tumor. After partial hepatic resection, specimens were histologically analyzed, and a complete loss of E-cadherin adhesion molecules was found. No oncogenic target mutations were found. The patient received a combination of conventional radiotherapy and peptide receptor radionuclide therapy (PRRT). Due to aggressive tumor behavior and rapid spread of metastases, the patient deceased after initiation of treatment.

Conclusions
E-cadherin downregulation is associated with a higher probability of tumor invasion and distant metastasis formation in malignant meningioma. Up to now, the efficacy of systemic therapy, including PRRT, is very limited in malignant meningioma patients.
KW  - beta-catenin
KW  - E-cadherin
KW  - meningioma
KW  - peptide receptor radionuclide therapy (PRRT)
KW  - radiotherapy
Y1  - 2023
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-357996
VL  - 23
ER  - 
TY  - JOUR
A1  - Werner, Rudolf A.
A1  - Higuchi, Takahiro
A1  - Pomper, Martin G.
A1  - Rowe, Steven P.
T1  - Theranostics in oncology — thriving, now more than ever
JF  - Diagnostics
N2  - Tracing its roots back to the 1940s, theranostics in nuclear oncology has proved successful mainly due to the beneficial effects of image-guided therapeutic concepts for patients afflicted with a variety of different cancers. The majority of these treatments are not only characterized by substantial prolongation of progression-free and overall survival, but are also generally safe, rendering theranostic agents as an attractive treatment option in various clinical scenarios in oncology. In this Special Issue Novel Theranostic Agents, nine original articles from around the globe provide further evidence on the use of the theranostic concept for neuroendocrine neoplasm (NEN), prostate cancer (PC), meningioma, and neuroblastoma. The investigated diagnostic and therapeutic radiotracers target not only established structures, such as somatostatin receptor, prostate-specific membrane antigen or norepinephrine transporter, but also recently emerging targets such as the C-X-C motif chemokine receptor 4. Moreover, the presented original articles also combine the concept of theranostics with in-depth read-out techniques such as radiomics or novel reconstruction algorithms on pretherapeutic scans, e.g., for outcome prediction. Even 80 years after its initial clinical introduction, theranostics in oncology continues to thrive, now more than ever.
KW  - theranostics
KW  - somatostatin receptor (SSTR)
KW  - prostate-specific membrane antigen (PSMA)
KW  - prostate cancer
KW  - neuroendocrine neoplasms (NEN)
KW  - neuroendocrine tumors (NET)
KW  - meningioma
KW  - norepinephrine transporter
KW  - neuroblastoma
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-236662
SN  - 2075-4418
VL  - 11
IS  - 5
ER  -